Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

Genetics: Expression signature identifies high-risk patients A gene expression signature identifies breast cancer patients who do poorly after endocrine therapy and might benefit from extra treatment. A team led by John Bartlett and Paul Boutros from the Ontario Institute for Cancer Research in Toro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jane Bayani, Cindy Q. Yao, Mary Anne Quintayo, Fu Yan, Syed Haider, Alister D’Costa, Cassandra L. Brookes, Cornelis J. H. van de Velde, Annette Hasenburg, Dirk G. Kieback, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Daniel Rea, Paul C. Boutros, John M. S. Bartlett
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e8e3e37c9ac342eb853c51e4f6f7efcc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e8e3e37c9ac342eb853c51e4f6f7efcc
record_format	dspace
spelling	oai:doaj.org-article:e8e3e37c9ac342eb853c51e4f6f7efcc2021-12-02T16:19:49ZMolecular stratification of early breast cancer identifies drug targets to drive stratified medicine10.1038/s41523-016-0003-52374-4677https://doaj.org/article/e8e3e37c9ac342eb853c51e4f6f7efcc2017-02-01T00:00:00Zhttps://doi.org/10.1038/s41523-016-0003-5https://doaj.org/toc/2374-4677Genetics: Expression signature identifies high-risk patients A gene expression signature identifies breast cancer patients who do poorly after endocrine therapy and might benefit from extra treatment. A team led by John Bartlett and Paul Boutros from the Ontario Institute for Cancer Research in Toronto, Canada, measured the activity levels of 165 genes known to be involved in breast cancer development in tumor samples from 3825 patients with early estrogen receptor-positive disease. The patients received either endocrine therapies (tamoxifen or an aromatase inhibitor) alone or additional chemotherapy as well. The researchers identified a 95-gene expression signature that, when combined with a determination of whether the cancer has spread into the lymph nodes, can help predict which patients are at high risk of disease progression, regardless of whether they received chemotherapy or not. These patients could be prioritized for additional drug therapies.Jane BayaniCindy Q. YaoMary Anne QuintayoFu YanSyed HaiderAlister D’CostaCassandra L. BrookesCornelis J. H. van de VeldeAnnette HasenburgDirk G. KiebackChristos MarkopoulosLuc DirixCaroline SeynaeveDaniel ReaPaul C. BoutrosJohn M. S. BartlettNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jane Bayani Cindy Q. Yao Mary Anne Quintayo Fu Yan Syed Haider Alister D’Costa Cassandra L. Brookes Cornelis J. H. van de Velde Annette Hasenburg Dirk G. Kieback Christos Markopoulos Luc Dirix Caroline Seynaeve Daniel Rea Paul C. Boutros John M. S. Bartlett Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
description	Genetics: Expression signature identifies high-risk patients A gene expression signature identifies breast cancer patients who do poorly after endocrine therapy and might benefit from extra treatment. A team led by John Bartlett and Paul Boutros from the Ontario Institute for Cancer Research in Toronto, Canada, measured the activity levels of 165 genes known to be involved in breast cancer development in tumor samples from 3825 patients with early estrogen receptor-positive disease. The patients received either endocrine therapies (tamoxifen or an aromatase inhibitor) alone or additional chemotherapy as well. The researchers identified a 95-gene expression signature that, when combined with a determination of whether the cancer has spread into the lymph nodes, can help predict which patients are at high risk of disease progression, regardless of whether they received chemotherapy or not. These patients could be prioritized for additional drug therapies.
format	article
author	Jane Bayani Cindy Q. Yao Mary Anne Quintayo Fu Yan Syed Haider Alister D’Costa Cassandra L. Brookes Cornelis J. H. van de Velde Annette Hasenburg Dirk G. Kieback Christos Markopoulos Luc Dirix Caroline Seynaeve Daniel Rea Paul C. Boutros John M. S. Bartlett
author_facet	Jane Bayani Cindy Q. Yao Mary Anne Quintayo Fu Yan Syed Haider Alister D’Costa Cassandra L. Brookes Cornelis J. H. van de Velde Annette Hasenburg Dirk G. Kieback Christos Markopoulos Luc Dirix Caroline Seynaeve Daniel Rea Paul C. Boutros John M. S. Bartlett
author_sort	Jane Bayani
title	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
title_short	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
title_full	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
title_fullStr	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
title_full_unstemmed	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
title_sort	molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e8e3e37c9ac342eb853c51e4f6f7efcc
work_keys_str_mv	AT janebayani molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT cindyqyao molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT maryannequintayo molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT fuyan molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT syedhaider molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT alisterdcosta molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT cassandralbrookes molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT cornelisjhvandevelde molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT annettehasenburg molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT dirkgkieback molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT christosmarkopoulos molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT lucdirix molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT carolineseynaeve molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT danielrea molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT paulcboutros molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine AT johnmsbartlett molecularstratificationofearlybreastcanceridentifiesdrugtargetstodrivestratifiedmedicine
_version_	1718384205835010048

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

Ejemplares similares